Compare DENN & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DENN | PRQR |
|---|---|---|
| Founded | 1953 | 2012 |
| Country | United States | Netherlands |
| Employees | 3800 | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 318.8M | 250.7M |
| IPO Year | 1989 | 2014 |
| Metric | DENN | PRQR |
|---|---|---|
| Price | $6.20 | $2.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $5.45 | ★ $8.14 |
| AVG Volume (30 Days) | ★ 2.3M | 540.5K |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $457,212,000.00 | $18,859,556.00 |
| Revenue This Year | $6.56 | N/A |
| Revenue Next Year | $1.56 | N/A |
| P/E Ratio | $31.61 | ★ N/A |
| Revenue Growth | ★ 0.93 | N/A |
| 52 Week Low | $2.85 | $1.07 |
| 52 Week High | $7.66 | $3.46 |
| Indicator | DENN | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 66.03 | 53.75 |
| Support Level | $6.13 | $2.15 |
| Resistance Level | $6.20 | $2.42 |
| Average True Range (ATR) | 0.02 | 0.19 |
| MACD | -0.04 | 0.04 |
| Stochastic Oscillator | 91.67 | 79.70 |
Denny's Corp is America's franchised full-service restaurant chains based on the number of restaurants. The company owns and operates the Denny's brand and the Keke's Breakfast Cafe brand. It provides Pancakes, Appetizers & Soups, Sandwiches & Salads, Breakfast Melts, Omelets, and others. The company generates its revenue from two sources: the sale of food and beverages and the collection of royalties, advertising revenue, initial and other fees, including occupancy revenue, from restaurants operated by their franchisees. Geographically operates in USA states as well as globally like Canada, Mexico, Guatemala, Indonesia, United Kingdom, New Zealand and others. Maximum revenue is from USA and Canada.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.